Open AccessImpact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial
Author(s) -
Véronique Avettand-Fènoël,
Philippe Flandre,
MarieLaure Chaix,
Jade Ghosn,
Constance Delaugerre,
François Raffi,
P. NgoVan,
Isabelle Cohen-Codar,
J. F. Delfraissy,
C. Rouzioux
Publication year - 2010
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkq084
Subject(s) - lopinavir , lopinavir/ritonavir , ritonavir , medicine , human immunodeficiency virus (hiv) , virology , pharmacology , viral load , antiretroviral therapy
To study the impact of protease inhibitor monotherapy on the HIV-1 blood reservoir in 72 antiretroviral-naive patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom